Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman speaks to Proactive about what the group managed to achieve in the first quarter of 2022. Namely, Lederman says the two main programs it focused on were its Phase 3 study to treat fibromyalgia, along with its program to treat Long COVID-19.
Tonix Pharmaceuticals talks through its 1Q 2022 financial and operational highlights
